Autologous Glypican-3-Targeted, Armored CAR T Cells in Patients with Advanced Solid Tumors: A Phase 1 Dose-Escalation Study of TAK-102

In this first-in-human, open-label, Phase I, dose-escalation study, researchers evaluated a single TAK-102 infusion in 11 patients with glypican-3-positive advanced solid tumors refractory or intolerant to standard therapies.